Last reviewed · How we verify
WINREVAIR (SOTATERCEPT-CSRK)
WINREVAIR (generic name: SOTATERCEPT-CSRK) is a drug developed by MERCK SHARP DOHME. It is currently FDA-approved for Pulmonary Arterial Hypertension.
Sotatercept-csrk binds to activin A and other TGF-β superfamily ligands, improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation.
WINREVAIR, also known as Sotatercept, is a protein inhibitor of the Inhibin beta A chain, which is being studied for the treatment of Pulmonary Arterial Hypertension and Pulmonary Artery Hypertension.
At a glance
| Generic name | SOTATERCEPT-CSRK |
|---|---|
| Sponsor | MERCK SHARP DOHME |
| Target | activin A and other TGF-β superfamily ligands |
| Therapeutic area | Other |
| Phase | FDA-approved |
Mechanism of action
Sotatercept-csrk is a fusion protein that inhibits activin signaling by binding to activin A and other related ligands. This binding helps to balance the signals that promote cell growth and those that inhibit it, which can reduce inflammation and prevent the overgrowth of cells in blood vessels affected by pulmonary arterial hypertension (PAH).
Approved indications
- Pulmonary Arterial Hypertension
Common side effects
- Headache
- Epistaxis
- Rash
- Telangiectasia
- Diarrhea
- Dizziness
- Erythema
- Infections
- Epistaxis
- Diarrhea
- Telangiectasia
Key clinical trials
- An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038) (Phase 3)
- A Single-arm, Open-label Phase IV Study to Evaluate the Effectiveness of Sotatercept in Improving Pulmonary Vascular Recruitment in Patients With Pulmonary Arterial Hypertension (PAH) (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WINREVAIR CI brief — competitive landscape report
- WINREVAIR updates RSS · CI watch RSS
- MERCK SHARP DOHME portfolio CI
Frequently asked questions about WINREVAIR
What is WINREVAIR?
How does WINREVAIR work?
What is WINREVAIR used for?
Who makes WINREVAIR?
What is the generic name of WINREVAIR?
What development phase is WINREVAIR in?
What are the side effects of WINREVAIR?
What does WINREVAIR target?
Related
- Target: All drugs targeting activin A and other TGF-β superfamily ligands
- Manufacturer: MERCK SHARP DOHME — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Pulmonary Arterial Hypertension